CompanyDrug

3SBio’s SSGJ-611 NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis

CompanyDrug

Kexing Biopharma’s GB19 Wins NMPA IND Approval – Novel BDCA2 Targeted Therapy for Lupus Enters Clinic

Lepu Biopharma's GPC3 ADC MRG006A Wins NMPA Approval for HCC Combination Trials – First‑in‑Class Asset Advances
CompanyDrug

Lepu Biopharma’s GPC3 ADC MRG006A Wins NMPA Approval for HCC Combination Trials – First‑in‑Class Asset Advances

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235
CompanyDeals

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235

FDA Approves AstraZeneca's Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen
CompanyDrug

FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label
CompanyDrug

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label

CompanyDrug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

CompanyDeals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

CompanyDrug

Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD

CompanyDeals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

CompanyDeals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

AbbVie Invests $380M in Illinois API Manufacturing – AI‑Enabled Facilities for Neuroscience and Obesity Drugs
Company

AbbVie Invests $380M in Illinois API Manufacturing – AI‑Enabled Facilities for Neuroscience and Obesity Drugs